MX2022009149A - Compuestos coagonistas de gip/glp1. - Google Patents
Compuestos coagonistas de gip/glp1.Info
- Publication number
- MX2022009149A MX2022009149A MX2022009149A MX2022009149A MX2022009149A MX 2022009149 A MX2022009149 A MX 2022009149A MX 2022009149 A MX2022009149 A MX 2022009149A MX 2022009149 A MX2022009149 A MX 2022009149A MX 2022009149 A MX2022009149 A MX 2022009149A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- gip
- relates
- present
- glp1
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a compuestos que tienen actividad tanto en los receptores del polipéptido insulinotrópico dependiente de glucosa (GIP) como en los receptores del péptido-1 similar al glucagón (GLP-1) humanos. La presente invención se refiere, además, a compuestos que tienen una duración de la acción prolongada en cada uno de estos receptores. Además, la presente invención se refiere a compuestos que pueden administrarse por vía oral. Estos compuestos pueden ser útiles en el tratamiento de la diabetes mellitus tipo 2 ("T2DM"). Estos compuestos pueden ser útiles en el tratamiento de la obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964932P | 2020-01-23 | 2020-01-23 | |
| PCT/US2021/014302 WO2021150673A1 (en) | 2020-01-23 | 2021-01-21 | Gip/glp1 co-agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009149A true MX2022009149A (es) | 2022-12-15 |
Family
ID=74592824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009149A MX2022009149A (es) | 2020-01-23 | 2021-01-21 | Compuestos coagonistas de gip/glp1. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230265151A1 (es) |
| EP (1) | EP4093757A1 (es) |
| JP (1) | JP2023511441A (es) |
| KR (1) | KR20220131292A (es) |
| CN (1) | CN115298207A (es) |
| AR (1) | AR121093A1 (es) |
| AU (1) | AU2021211451B2 (es) |
| BR (1) | BR112022014397A2 (es) |
| CA (1) | CA3165430A1 (es) |
| IL (1) | IL294955A (es) |
| MX (1) | MX2022009149A (es) |
| TW (1) | TWI770781B (es) |
| WO (1) | WO2021150673A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| EP4294423A1 (en) * | 2021-02-17 | 2023-12-27 | Eli Lilly and Company | Gip/glp1 dual agonist therapeutic methods |
| CA3224598A1 (en) | 2021-08-30 | 2023-03-09 | Long Zhang | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| KR102873595B1 (ko) | 2021-09-15 | 2025-10-22 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 장애의 치료를 위한 조성물 및 방법 |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
| CN116023444B (zh) * | 2022-08-12 | 2023-08-01 | 重庆宸安生物制药有限公司 | 一种gip和glp-1双受体激动剂多肽化合物及其应用 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| CN103764673A (zh) * | 2011-06-10 | 2014-04-30 | 北京韩美药品有限公司 | 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用 |
| WO2013164483A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| SG11201503526UA (en) * | 2012-12-21 | 2015-06-29 | Sanofi Sa | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| EP3065767B1 (en) * | 2013-11-06 | 2020-12-30 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| TWI669309B (zh) * | 2015-06-22 | 2019-08-21 | 美商美國禮來大藥廠 | 升糖素及ｇｌｐ－１共激動劑化合物 |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TW202523681A (zh) * | 2018-07-23 | 2025-06-16 | 美商美國禮來大藥廠 | Gip/glp1共促效劑化合物 |
-
2021
- 2021-01-21 WO PCT/US2021/014302 patent/WO2021150673A1/en not_active Ceased
- 2021-01-21 IL IL294955A patent/IL294955A/en unknown
- 2021-01-21 AU AU2021211451A patent/AU2021211451B2/en active Active
- 2021-01-21 MX MX2022009149A patent/MX2022009149A/es unknown
- 2021-01-21 EP EP21705072.3A patent/EP4093757A1/en active Pending
- 2021-01-21 US US17/794,128 patent/US20230265151A1/en active Pending
- 2021-01-21 JP JP2022544753A patent/JP2023511441A/ja active Pending
- 2021-01-21 BR BR112022014397A patent/BR112022014397A2/pt unknown
- 2021-01-21 TW TW110102332A patent/TWI770781B/zh active
- 2021-01-21 AR ARP210100135A patent/AR121093A1/es unknown
- 2021-01-21 CN CN202180023819.8A patent/CN115298207A/zh active Pending
- 2021-01-21 KR KR1020227028667A patent/KR20220131292A/ko not_active Withdrawn
- 2021-01-21 CA CA3165430A patent/CA3165430A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3165430A1 (en) | 2021-07-29 |
| CN115298207A (zh) | 2022-11-04 |
| AU2021211451B2 (en) | 2023-11-02 |
| AU2021211451A1 (en) | 2022-08-18 |
| TWI770781B (zh) | 2022-07-11 |
| WO2021150673A1 (en) | 2021-07-29 |
| EP4093757A1 (en) | 2022-11-30 |
| IL294955A (en) | 2022-09-01 |
| TW202140528A (zh) | 2021-11-01 |
| BR112022014397A2 (pt) | 2022-10-11 |
| JP2023511441A (ja) | 2023-03-17 |
| AR121093A1 (es) | 2022-04-20 |
| US20230265151A1 (en) | 2023-08-24 |
| KR20220131292A (ko) | 2022-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202106369B (en) | Gip/glp1 co-agonist compounds | |
| MX2022009149A (es) | Compuestos coagonistas de gip/glp1. | |
| SA522431576B1 (ar) | مركبات مساعدة لمستقبل بشري لبولي ببتيد مفرز للإنسولين يتوقف على الجلوكوز | |
| Gasbjerg et al. | Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists | |
| MX2023002906A (es) | Agonistas duales glp-1/gip. | |
| WO2020207477A9 (zh) | 一种多受体激动剂及其医药用途 | |
| JP2014504588A5 (es) | ||
| MX2023000303A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. | |
| IN2012DN03921A (es) | ||
| EA200100289A1 (ru) | Способ введения инсулинотропных пептидов | |
| PH12022553526A1 (en) | Long acting glp-1/gip dual agonists | |
| ATE480259T1 (de) | Intranasale verabreichung von glucose- regulierenden peptiden | |
| DK1523325T3 (da) | Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom | |
| EP2070946A3 (de) | Erfindung betreffend GLP-1 und Exendin | |
| MX2023014740A (es) | Tratamiento de la obesidad y trastornos relacionados con la obesidad. | |
| MX2025011217A (es) | Analogo de incretina y uso del mismo | |
| EP4272823A3 (en) | Pharmaceutical composition for treating sarcopenia comprising glucagon-like peptide-1 receptor agonist | |
| EA202192296A1 (ru) | Терапевтическое применение дулаглутида | |
| EA202092891A1 (ru) | Соединения-коагонисты gip/glp1 | |
| TH2101000319A (th) | สารประกอบอะโกนิสท์ร่วม gip/glp1 | |
| EA202092017A1 (ru) | Новые аналоги glp-1 | |
| NZ772008A (en) | Gip/glp1 co-agonist compounds | |
| NZ772008B2 (en) | Gip/glp1 co-agonist compounds | |
| Perušičová | Inkretinová strategie léčby diabetes mellitus 2. typu-DPP-IV | |
| TH2001005828A (th) | Glp-1 อนาล็อกชนิดใหม่ |